New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease.
Canaan adds $100M+ to boost biopharma investing, brings on former Pfizer exec
Canaan, a decades-old tech and life sciences venture capital firm, plans to invest more heavily in biopharma going forward. The Menlo Park, CA-based firm added